HIGH TUMOUR INTRINSIC EXPRESSION OF STING IS ASSOCIATED WITH POTENT AND TP53 INDEPENDENT PRO-APOPTOTIC ACTIVITY BY STING AGONISTS IN AML

EHA Library, Yin Yuan, 422227

CPSF6-RARG FUSION COOPERATES HDAC3 TO PROMOTE MYELOID TRANSFORMATION BY DOWNREGULATING PU.1

EHA Library, Tanzhen Wang, 422228

KMT2A-MLLT3-INDUCED LEUKAEMIA CHANGES DURING ONTOGENIC STAGES

EHA Library, Meaad Almowaled, 422229

CHROMATIN ACCESSIBILITY PROFILING REVEALS EPIGENETIC HETEROGENEITY IN ACUTE MYELOID LEUKEMIA

EHA Library, Yotaro Ochi, 422230

THE ONCOGENIC ACTIVITY OF THE INTRINSICALLY DISORDERED TRANSCRIPTIONAL REGULATOR MN1 RELIES ON THE CHAPERONE DNAJB6B IN ACUTE MYELOID LEUKEMIA

EHA Library, Diego A Pereira-Martins, 422231

MEGAKARYOBLASTIC LEUKEMIA SPECIFIC DEPENDENCY ON LONG NON-CODING RNA SNHG29

EHA Library, Robert Winkler, 422232

PREEMPTIVE TARGETING OF PRELEUKEMIC CELLS IN DOWN SYNDROME WITH PATHWAY-DIRECTED THERAPIES: A NOVEL APPROACH TO PREVENT MYELOID LEUKEMIA

EHA Library, Anna-Lena Schmell, 422233

THE NOVEL MENIN INHIBITOR ZE63-0302 HAS AN IMPRESSIVE SAFETY PROFILE AND UNIQUE CHEMISTRY THAT SUGGESTS IMPROVED EFFICACY AGAINST RESISTANCE MUTATIONS.

EHA Library, Erin Hertlein, 422234

FIRST-IN-HUMAN PHASE 1/2 STUDY OF THE MENIN-MLL INHIBITOR DSP-5336 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LEUKEMIA: UPDATED RESULTS FROM DOSE ESCALATION

EHA Library, Naval Daver, 422236

A PHASE 1B STUDY OF THE MENIN-KMT2A INHIBITOR JNJ-75276617 IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH ALTERATIONS IN KMT2A OR NPM1

EHA Library, Andrew H. Wei, 422237

PHASE 1B STUDY OF AZACITIDINE, VENETOCLAX AND REVUMENIB IN NEWLY DIAGNOSED OLDER ADULTS WITH NPM1 MUTATED OR KMT2A REARRANGED AML: INTERIM RESULTS OF DOSE ESCALATION FROM THE BEATAML CONSORTIUM

EHA Library, Joshua Zeidner, 422238

VENETOCLAX-BASED SALVAGE TREATMENT FOR RELAPSED/REFRACTORY AML USING A COMBINATION WITH HIGH-DOSE CYTARABINE AND MITOXANTRONE (HAM-VEN): UPDATED RESULTS OF THE PHASE-I/II SAL RELAX TRIAL

EHA Library, Leo Ruhnke, 422239

FLAG-IDA + VENETOCLAX (VEN) IN NEWLY DIAGNOSED (ND) OR RELAPSED / REFRACTORY (RR) AML

EHA Library, Wei-Ying Jen, 422240

VENETOCLAX-HMA AS A BRIDGE TOWARDS HSCT OR DLI IN R/R AML: A RETROSPECTIVE ANALYSIS IN 20 HOSPITALS ACROSS THE NETHERLANDS

EHA Library, Kathelijn Verdeyen, 422241

MAGROLIMAB VS PLACEBO IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: THE ENHANCE-3 STUDY

EHA Library, Naval Daver, 422242

PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Alex Bataller, 422243

LLS 2024 ELN-REFINED RISK STRATIFICATION IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH LOW-INTENSITY THERAPY

EHA Library, Fieke Hoff, 422244

A POST HOC ANALYSIS OF OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES WHO RECEIVED ORAL AZACITIDINE MAINTENANCE THERAPY IN THE QUAZAR AML-001 STUDY

EHA Library, Maria Teresa Voso, 422245

QUANTUM-FIRST: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FMS-LIKE TYROSINE KINASE 3-INTERNAL TANDEM DUPLICATION–POSITIVE (FLT3-ITD+) ACUTE MYELOID LEUKEMIA (AML) WHO RECEIVED CONTINUATION THERAPY

EHA Library, Mikkael A. Sekeres, 422246

DISEASE CHARACTERISTICS AND OUTCOME OF ACUTE MYELOID LEUKEMIA IN FAMILIAL PLATELET DISORDER WITH ASSOCIATED MYELOID MALIGNANCY

EHA Library, Martijn Ernst, 422247

OLUTASIDENIB FOR MUTATED IDH1 ACUTE MYELOID LEUKEMIA: FINAL FIVE-YEAR RESULTS FROM THE PHASE 2 PIVOTAL COHORT

EHA Library, Jorge Cortes, 422248

GENETIC INSIGHTS INTO ACQUIRED RESISTANCE AND CLONAL EVOLUTION IN VENETOCLAX (VEN)-BASED THERAPY FOR ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Marina Konopleva, 422249

COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY OF CD123 NK CELL ENGAGER, SAR443579, IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR HIGH RISK-MYELODYSPLASIA

EHA Library, Sylvain Garciaz, 422250

ADVERSE PROGNOSTIC IMPACT OF SECONDARY-TYPE MUTATIONS IN ELN 2022 FAVORABLE RISK ACUTE MYELOID LEUKEMIA

EHA Library, Dimitrios Kotsos, 422251

GENOMIC LANDSCAPE OF ADULT AML WITH T(8;21)(Q22;Q22.1) AND PROGNOSTIC IMPLICATIONS – RESULTS FROM THE HARMONY PLATFORM

EHA Library, Alberto Hernandez-Sanchez, 422252

MINI-CONSOLIDATIONS VERSUS INTERMEDIATE-DOSE CYTARABINE (IDAC) FOR THE POST-REMISSION THERAPY OF AML PATIENTS OVER 60. A STUDY FROM THE DATAML AND SAL REGISTRIES.

EHA Library, Christian Récher, 422253

COMPREHENSIVE FUNCTIONAL ANALYSES OF LEF1 IDENTIFY PROTEIN ABUNDANCE AND ALTERNATIVE ISOFORM EXPRESSION AS DRIVERS OF CELL PROLIFERATION IN AGGRESSIVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Judith Mateos-Jaimez, 422254

SINGLE-CELL ANALYSES AND FUNCTIONAL IN VIVO STUDIES IDENTIFY IMMATURE SUPPRESSIVE NEUTROPHILS THAT LIMIT T-CELL CONTROL OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Martina Seiffert, 422255

INTEGRATIVE SINGLE-CELL ANALYSES OF CIRCULATING CELLS FROM LEUKEMIC AND HEALTHY SIBLINGS IN FAMILIAL FORMS OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Mira CHEMLA KUZMIC, 422256

CD49D DEFICIENCY IN A CHRONIC LYMPHOCYTIC LEUKEMIA MODEL INDUCES CONSTITUTIVE B CELL RECEPTOR KINASE ACTIVATION, RESULTING IN ANTIGEN UNRESPONSIVENESS

EHA Library, Laura Polcik, 422257

FIRST-IN-CLASS MTHFD1 INHIBITOR ELIMINATES MALIGNANT B CELLS IN VITRO AND IN VIVO

EHA Library, Elodie Viry, 422258

LATEST RESULTS FROM AN ONGOING FIRST-IN-HUMAN PHASE 1A/B STUDY OF NX-5948, A SELECTIVE BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY CLL AND OTHER B-CELL MALIGNANCIES

EHA Library, Kim Linton, 422259

RESULTS FROM THE PHASE 1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (SONRO) IN COMBINATION WITH ZANUBRUTINIB (ZANU) FOR RELAPSED/REFRACTORY (R/R) CLL/SLL SHOW DEEP AND DURABLE RESPONSES

EHA Library, Stephen Opat, 422260

PRELIMINARY EFFICACY AND SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL: RESULTS FROM THE PHASE 1 BGB-16673-101 STUDY

EHA Library, Ricardo Parrondo, 422261

CHARACTERISTICS ASSOCIATED WITH RESPONSE TO LISOCABTAGENE MARALEUCEL (LISO‑CEL) IN PATIENTS (PTS) WITH R/R CLL/SLL: EXPLORATORY ANALYSES FROM TRANSCEND CLL 004

EHA Library, William G. Wierda, 422262

EFFECTIVENESS OF OBINUTUZUMAB, ALONE AND COMBINED WITH THE BRAF INHIBITOR VEMURAFENIB, IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA (R/R HCL): A MULTICENTER PHASE-2 TRIAL

EHA Library, Enrico Tiacci, 422263

COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT-NAIVE (TN) CLL/SLL WITH DEL(17P) AND/OR TP53: PRELIMINARY RESULTS FROM SEQUOIA ARM D

EHA Library, Paolo Ghia, 422264

MINIMAL RESIDUAL DISEASE-GUIDED COMBINATION OF IBRUTINIB PLUS VENETOCLAX COMPARED TO FCR IN UNTREATED PATIENTS WITH CLL OF INTERMEDIATE RISK : INTERIM RESULTS FROM THE PHASE II FILO TRIAL.

EHA Library, Anne-Sophie Michallet, 422265

7-YEAR UPDATE ON A PHASE 2 TRIAL OF FIXED-DURATION OBINUTUZUMAB, IBRUTINIB, AND VENETOCLAX FOR CLL

EHA Library, Kerry Rogers, 422266

SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL

EHA Library, Arnon P. Kater, 422267

COMBINED PIRTOBRUTINIB, VENETOCLAX, AND OBINUTUZUMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PHASE 2 TRIAL

EHA Library, Nitin Jain, 422268

DEVELOPMENT OF A PROGNOSTIC SCORING SYSTEM FOR CHRONIC MYELOID LEUKEMIA IN BLAST PHASE: INSIGHTS FROM THE EUROPEAN LEUKEMIANET BLAST PHASE REGISTRY

EHA Library, Michael Lauseker, 422269

A MACHINE LEARNING APPROACH IDENTIFIES A 27-GENE TRANSCRIPTOMIC SIGNATURE PREDICTING TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Franck Emmanuel Nicolini, 422270

A NOVEL IMMUNE-RELATED SCORE PREDICTS DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) TREATED UP-FRONT WITH TYROSINE KINASE INHIBITORS (TKI)

EHA Library, Janine Steichen, 422271

COMBINATORY THERAPY OF PONATINIB AND VENETOCLAX WAS EFFECTIVE IN THE TREATMENT OF ASCIMINIB-RESISTANT CHRONIC MYELOID LEUKEMIA IN VIVO

EHA Library, Nikola Čuřík, 422272

A NOVEL CIP2A AND BCL-XL CLINICAL DIAGNOSTIC TOOLKIT TO PREDICT DISEASE PROGRESSION AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA.

EHA Library, Claire c.lucas@chester.ac.uk, 422273

PONATINIB AND 5-AZACYTIDINE FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA IN MYELOID BLAST CRISIS . RESULTS OF THE PONAZA TRIAL (NCT03895671).

EHA Library, Philippe Rousselot, 422274

SUSTRENIM TRIAL: SUSTAINED DEEP MOLECULAR RESPONSE AND TFR RATE IN THE LONG-TERM FOLLOW-UP

EHA Library, Massimo Breccia, 422275

IMPROVED TOLERABILITY WITH DASATINIB 5 DAYS COMPARED TO 7 DAYS PER WEEK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. FINAL RESULTS OF THE DASAHIT TRIAL.

EHA Library, Paul La Rosée, 422276

OUTCOMES WITH PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AND THE T315I MUTATION: 4-YEAR RESULTS FROM THE OPTIC TRIAL

EHA Library, Jane Apperley, 422277

A PHASE 2, RANDOMIZED TRIAL OF RUXOLITINIB IN ADDITION TO BCR::ABL1 TKIS IN CML PATIENTS WITH MOLECULAR EVIDENCE OF DISEASE (SWOG TRIAL S1712)

EHA Library, Kendra Sweet, 422278

MDS DIAGNOSIS AND RISK STRATIFICATION BASED ON SINGLE CELL RNA-SEQ OF CIRCULATING HSPCS

EHA Library, Nili Furer, 422279

SEX DIFFERENCES IN DNMT3A-MUTANT CLONAL HEMATOPOIESIS AND THE EFFECTS OF ESTROGEN

EHA Library, Julia Stomper, 422280

TARGETING MCL1-DRIVEN ANTI-APOPTOTIC PATHWAYS OVERCOMES BLAST PROGRESSION AFTER HYPOMETHYLATING AGENT RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 422281

SINGLE-CELL T-CELL LANDSCAPE IN MYELODYSPLASTIC SYNDROMES DURING VENETOCLAX THERAPY

EHA Library, Juan Jose Rodriguez-Sevilla, 422282

DISCOVERY AND DEVELOPMENT OF CLL-1 AS A CELLULAR IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Juwita Werner, 422283

PRIMARY RESULTS OF THE PHASE III STIMULUS-MDS2 STUDY OF SABATOLIMAB + AZACITIDINE VS PLACEBO + AZACITIDINE AS FRONTLINE THERAPY FOR PATIENTS WITH HIGHER-RISK MDS OR CMML-2

EHA Library, Amer M. Zeidan, 422284

MAGROLIMAB (MAGRO) + AZACITIDINE (AZA) VS PLACEBO (PBO) + AZA IN PATIENTS (PTS) WITH UNTREATED HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS): PHASE 3 ENHANCE STUDY FINAL ANALYSIS

EHA Library, David Sallman, 422285

IVOSIDENIB MONOTHERAPY IN IDH1 MUTATED MYELODYSPLASTIC SYNDROME, FINAL RESULTS OF THE IDIOME TRIAL, A GFM STUDY

EHA Library, Marie Sébert, 422286

DURABLE CLINICAL BENEFIT WITH ELRITERCEPT (KER-050) TREATMENT: FINDINGS FROM AN ONGOING PHASE 2 TRIAL IN PARTICIPANTS WITH LOWER-RISK MDS

EHA Library, María Díez Campelo, 422287

OVERALL SURVIVAL, CLINICAL BENEFIT, AND DURABLE TRANSFUSION INDEPENDENCE WITH IMETELSTAT IN THE IMERGE PHASE 3 TRIAL OF RED BLOOD CELL-TRANSFUSION DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES

EHA Library, Valeria Santini, 422288

FUNCTIONAL CHARACTERIZATION OF DDX41 VARIANTS

EHA Library, Nikolaj Nitschke, 422289

SINGLE-CELL TRANSCRIPTOMIC ANALYSIS IDENTIFIES AN ENDOTHELIAL CELL-LIKE MACROPHAGE POPULATION THAT IS DEFICIENT IN PATIENTS WITH APLASTIC ANEMIA

EHA Library, Chenyuan Li, 422290

KP104, A BIFUNCTIONAL C5 MAB-FACTOR H FUSION PROTEIN, EFFECTIVELY CONTROLS INTRAVASCULAR AND EXTRAVASCULAR HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS: LONG-TERM RESULTS FROM A PHASE 2 STUDY

EHA Library, Bing Han, 422291

DANICOPAN AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS: PHASE 3 LONG-TERM DATA

EHA Library, Austin Kulasekararaj, 422292

OMS906, A NOVEL ALTERNATIVE PATHWAY MASP-3 INHIBITOR, IMPROVED HEMATOLOGIC PARAMETERS IN PNH PATIENTS WITH SUBOPTIMAL RESPONSE TO RAVULIZUMAB TREATMENT: PHASE 2 DOSE-FINDING STUDY INTERIM RESULTS

EHA Library, Morag Griffin, 422293

INHIBITION OF PI3K IMPROVES MEMORY FORMATION AND MITOCHONDRIAL HEALTH IN T CELLS FROM CLL PATIENTS, LEADING TO HIGHER ANTI-TUMOR ACTIVITY OF CAR T CELLS

EHA Library, Helga Simon-Molas, 422294

IMPACT OF TREATMENT WITH IBRUTINIB OR VENETOCLAX ON CAR T CELLS GENERATED FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PRELIMINARY ANALYSIS OF THE GIMEMA CLL2020 STUDY

EHA Library, Marta Coscia, 422295

IMPACT OF T-CELL CHARACTERISTICS ON RESPONSE AND RESISTANCE TO T-CELL REDIRECTING BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA

EHA Library, Christie Verkleij, 422296

ARI0002H, AN ACADEMIC CAR-T AGAINST BCMA IN MULTIPLE MYELOMA,  PRESENTS A MORE POTENT ANTITUMORAL ACTIVITY WHEN USING A TRANSMEMBRANE CD28 DOMAIN

EHA Library, Oriol Cardús, 422297

SEQUENTIAL ADMINISTRATION OF BISPECIFIC ANTIBODIES AND ANTI-BCMA CAR-T CELL THERAPY IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA IS ASSOCIATED WITH EXPANSION OF CD8 EFFECTOR CLONES AND HIGH RESPONSE RATES

EHA Library, David Fandrei, 422298

COMBINED INHIBITION OF CTPS1 AND ATR IS A METABOLIC VULNERABILITY IN P53-DEFICIENT MYELOMA CELLS

EHA Library, Catherine Pellat, 422299

INVESTIGATING THE FUNCTIONAL AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN MULTIPLE MYELOMA PATHOGENESIS

EHA Library, Marta Lionetti, 422300

GENOMIC LANDSCAPE OF IGM MGUS AND STABLE VERSUS PROGRESSIVE ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA PATIENTS

EHA Library, Tina Bagratuni, 422301

BONE MARROW ECOSYSTEMS SHAPE SECONDARY RESISTANCE TO ANTI-CD38 TREATMENT IN MULTIPLE MYELOMA

EHA Library, Yang Liang, 422302

LANDSCAPE OF IMMUNE SYSTEM IMPAIRMENT AND GUT MICROBIOTA COMPOSITION ALONG MULTIPLE MYELOMA EVOLUTION FROM PREMALIGNANT CONDITIONS

EHA Library, Cirino Botta, 422303

A PHASE I OPEN-LABEL SINGLE-ARM STUDY OF DUAL TARGETING BCMA AND CD19 FASTCAR-T (GC012F) AS FIRST-LINE THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA

EHA Library, Juan Du, 422304

DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF MINIMAL RESIDUAL DISEASE IN THE PERSEUS TRIAL

EHA Library, Pieter Sonneveld, 422305

ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE FOR NEWLY-DIAGNOSED, TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA: POST TRANSPLANTATION INTERIM ANALYSIS OF THE RANDOMIZED PHASE III GMMG-HD7 TRIAL

EHA Library, Marc S. Raab, 422306

RANDOMIZED PHASE 3 STUDY OF ISATUXIMAB (ISA) PLUS LENALIDOMIDE AND DEXAMETHASONE (RD) WITH BORTEZOMIB (V) VERSUS ISARD IN PATIENTS WITH NEWLY DIAGNOSED TRANSPLANT INELIGIBLE MULTIPLE MYELOMA (NDMM TI)

EHA Library, Xavier Leleu, 422307

DARATUMUMAB (DARA) + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) FOLLOWED BY DARA MAINTENANCE IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): >6-YEAR UPDATE OF CASSIOPEIA

EHA Library, Philippe Moreau, 422308

CILTACABTAGENE AUTOLEUCEL ± LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA WITH SUBOPTIMAL RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANT: CARTITUDE-2 COHORT D

EHA Library, Wilfried Roeloffzen, 422309

EQUE-CEL, A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T THERAPY IN PATIENTS WITH HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Lijuan Chen, 422310

PHASE 1 STUDY OF ANITOCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM AT LEAST 1-YEAR FOLLOW-UP IN ALL PATIENTS

EHA Library, Matthew Frigault, 422311

IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS (PTS) WITH CLINICAL HIGH-RISK EARLY RELAPSE MULTIPLE MYELOMA (MM) WITHOUT FRONT-LINE (1L) AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): KARMMA-2 COHORT 2B

EHA Library, Xavier Leleu, 422312

PHASE 2 STUDY OF FULLY HUMAN BCMA-TARGETING CAR-T CELLS (ZEVORCABTAGENE AUTOLEUCEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Wenming Chen, 422313

CEVOSTAMAB IN PATIENTS WITH RRMM WHO ARE TRIPLE-CLASS REFRACTORY AND HAVE RECEIVED A PRIOR BCMA-TARGETED ADC OR CAR T-CELL: INITIAL RESULTS FROM THE PHASE I/II CAMMA 2 STUDY

EHA Library, Shaji Kumar, 422314

EFFICACY, SAFETY, AND DETERMINATION OF RP2D OF ABBV-383, A BCMA BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

EHA Library, Katja Weisel, 422315

LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE LINKER-MM1 STUDY: DEPTH AND DURABILITY OF RESPONSE AT 14-MONTH MEDIAN FOLLOW-UP

EHA Library, Suzanne Lentzsch, 422316

OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING EARLY PROGRESSION AFTER IDE-CEL THERAPY: AN IFM STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Cayla Sarah, 422317

RESULTS FROM DREAMM-7 A RANDOMIZED PHASE 3 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 422318

SPATIAL TRANSCRIPTOMIC CHARACTERISATION OF THE BONE MARROW LANDSCAPE

EHA Library, Rosalin Cooper, 422319

DEVELOPMENT AND EVALUATION OF A NOVEL CAR-T CELL THERAPY AGAINST CALRETICULIN MUTANT NEOPLASMS

EHA Library, Alexandros Rampotas, 422320

ANALYSIS OF MOLECULAR MECHANISMS AND PREDICTIVE BIOMARKERS OF DISEASE TRANSFORMATION IN POLYCYTHEMIA VERA

EHA Library, Michael Grunwald, 422321

UPDATED LONG-TERM RESULTS FROM THE PHASE 2 REVIVE STUDY INVESTIGATING THE HEPCIDIN MIMETIC RUSFERTIDE IN POLYCYTHEMIA VERA PATIENTS (PTS): HEMATOCRIT CONTROL AND THERAPEUTIC PHLEBOTOMY (TP) FREQUENCY

EHA Library, Kristen Pettit, 422322

JAK2V617F MOLECULAR RESPONSE CORRELATES WITH EVENT-FREE SURVIVAL IN AN EARLY POLYCYTHEMIA VERA POPULATION

EHA Library, Jean-Jacques Kiladjian, 422323

PELABRESIB PLUS RUXOLITINIB COMBINATION THERAPY IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS IN THE MANIFEST-2 STUDY: PRELIMINARY EVIDENCE OF BONE MARROW RECOVERY

EHA Library, Raajit K Rampal, 422324

SAFETY AND EFFICACY OF PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: LATEST DATA FROM THE PHASE 3 MANIFEST-2 STUDY

EHA Library, Raajit K Rampal, 422325

EFFICACY AND SAFETY OF NAVITOCLAX IN COMBINATION WITH RUXOLITINIB VERSUS RUXOLITINIB PLUS PLACEBO IN PATIENTS WITH UNTREATED MYELOFIBROSIS IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND TRANSFORM-1 STUDY

EHA Library, Naveen Pemmaraju, 422326

ELRITERCEPT (KER-050) DEMONSTRATED POTENTIAL TO TREAT MYELOFIBROSIS AND MITIGATE RUXOLITINIB-ASSOCIATED CYTOPENIAS IN THE PHASE 2 RESTORE TRIAL

EHA Library, Claire Harrison, 422327